M
Michael Pfreundschuh
Researcher at Saarland University
Publications - 566
Citations - 34079
Michael Pfreundschuh is an academic researcher from Saarland University. The author has contributed to research in topics: Antigen & Rituximab. The author has an hindex of 86, co-authored 563 publications receiving 30972 citations. Previous affiliations of Michael Pfreundschuh include University of Hamburg & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh,Lorenz Trümper,Anders Österborg,Ruth Pettengell,Marek Trneny,Kevin Imrie,David D.F. Ma,Devinder Gill,Jan Walewski,Pier Luigi Zinzani,Rolf A. Stahel,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Tuula Lehtinen,Armando López-Guillermo,Claudia Corrado,Adriana Scheliga,Noel Milpied,Myriam Mendila,Michelle Rashford,Evelyn Kuhnt,Markus Loeffler +23 more
TL;DR: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Journal ArticleDOI
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Yao-Tseng Chen,Matthew J. Scanlan,Ugur Sahin,Özlem Türeci,Ali O. Gure,Solam Tsang,Barbara Williamson,Elisabeth Stockert,Michael Pfreundschuh,Lloyd J. Old +9 more
TL;DR: R reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma, which indicates that it belongs to an expanding family of immunogenic testicular antigens.
Journal ArticleDOI
Human neoplasms elicit multiple specific immune responses in the autologous host.
Ugur Sahin,Özlem Türeci,Holger Schmitt,Bjorn Cochlovius,Thomas Johannes,Rudolf Schmits,Frank Stenner,Guorong Luo,Ingrid Schobert,Michael Pfreundschuh +9 more
TL;DR: The unexpected frequency of human tumor antigens indicates that human neoplasms elicit multiple specific immune responses in the autologous host and provides diagnostic and therapeutic approaches to human cancer.
Journal ArticleDOI
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Atanas Kamburov,Robert A. Redd,Michael S. Lawrence,Michael S. Lawrence,Margaretha G.M. Roemer,Amy Li,Marita Ziepert,Annette M. Staiger,Annette M. Staiger,Jeremiah Wala,Matthew D. Ducar,Ignaty Leshchiner,Ester Rheinbay,Amaro Taylor-Weiner,Caroline A. Coughlin,Julian M. Hess,Chandra Sekhar Pedamallu,Dimitri Livitz,Daniel Rosebrock,Mara Rosenberg,Adam Tracy,Heike Horn,Paul Van Hummelen,Andrew L. Feldman,Brian K. Link,Anne J. Novak,James R. Cerhan,Thomas M. Habermann,Reiner Siebert,Andreas Rosenwald,Aaron R. Thorner,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Rameen Beroukhim,Rameen Beroukhim,Gerald Wulf,German Ott,Scott J. Rodig,Scott J. Rodig,Stefano Monti,Donna Neuberg,Markus Loeffler,Michael Pfreundschuh,Lorenz Trümper,Gad Getz,Gad Getz,Margaret A. Shipp +52 more
TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
Journal ArticleDOI
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster,Martin Dreyling,Wolfram Klapper,Christian Gisselbrecht,Achiel Van Hoof,Hanneke C. Kluin-Nelemans,Michael Pfreundschuh,Marcel Reiser,Bernd Metzner,H. Einsele,Norma Peter,Wolfram Jung,Bernhard Wörmann,Wolf-Dieter Ludwig,Ulrich Dührsen,Hartmut Eimermacher,Hannes Wandt,Joerg Hasford,Wolfgang Hiddemann,Michael Unterhalt +19 more
TL;DR: The MIPI as discussed by the authors is the first prognostic index particularly suited for mantle cell lymphoma patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.